Mittal, Richa,Chhabra,etc.GOLD Classification of COPD: Discordance in Criteria for Symptoms and Exacerbation Risk Assessment[J].2017,14(1).Mittal R, Chhabra SK, Mittal R, et al. GOLD classifica- tion of COPD : discordance in criteria for symptoms and exacerbation risk assessment gold ...
COPD分级分期（stage），分级（grade）BODE，MRC，CAT,AE 诊断标准postFEV1/FVC,LLN，FEV1/FVC+症状问卷，PEF，COPD-6，联合 ClassificationofCOPDSeveritybySpirometry StageI:Mild FEV1/FVC<0.70FEV1>80%predicted StageII:Moderate FEV1/FVC<0.7050%<FEV1<80%predicted StageIII:Severe FEV1/FVC<0.7030%<FEV1<...
GOLD classification of COPD: discordance in criteria for symptoms and exacerbation risk assessment. COPD. 2017;14(1):1-6. doi:10.1080/15412555.2016.1230844 PubMedGoogle ScholarCrossref 9. Moya-Álvarez V, Quevedo-Marín JL, Ji Z, et al. Variation in assignment of the...
[16] Zogg S,Durr S,Miedinger D,et al.Differences in classification of COPD patients into risk groups AD: a cross-sectional study.BMC Res Notes,2014,7:562. [17] Mohan A,Sethi S.The reliability and validity of pat...
GOLD 2023 慢阻肺定义:慢性阻塞性肺疾病(COPD)是一种异质性肺部状态,其特征是慢性呼吸系统症状(呼吸困难、咳嗽、咳痰),原因与气道异常(支气管炎、细支气管炎)和/或肺泡(肺气肿)相关,通常表现为持续性、进行性加重的气流阻塞。 新定义未提及慢阻肺是一...
GOLD 2011分类方法对 COPD 患者评估的初步探索 Objective To observe whether differences exist between theassessment method of the GOLD 201 1 new classification and that of the GOLD 2007 in the evaluatio... 熊鑫,芦丽瑾,孙永昌 - 《国际呼吸杂志》 被引量: 0发表: 2014年 GOLD2011分类方法对COPD患者评...
(grade) BODE,MRC,CAT,AE 诊断标准 post FEV1/FVC, LLN,FEV1/FVC + 症状 问卷,PEF,COPD-6,联合 Classification of COPD Severity by Spirometry Stage I: Mild FEV1/FVC 0.70 FEV1 80% predicted Stage II: Moderate FEV1/FVC 0.70 50% FEV1 80% predicted Stage III: Severe FEV1/FVC 0.70 30% FEV1 ...
临床指南:呼吸科-2017 GOLD慢性阻塞性肺疾病全球倡议:COPD诊断、治疗与预防全球策略(中文版).pdf,慢性阻塞性肺疾病 全球倡议 慢性阻塞性肺疾病 诊断、治疗 和预防的全球策略 2017 报告 一 GOLD2017 中文版报告核心专家组成员 钟南山 王辰 陈荣昌 姚婉贞 蔡柏蔷 康健 文
Harlander, Matevz, et al. 'Should Patients Switched from D to B in the GOLD 2017 Classification be Discontinued from Inhaled Corticosteroids?.' COPD: Journal of Chronic Obstructive Pulmonary Disease 14.5 (2017): 465-468. Vogelmeier C, Worth H, Buhl R, et al. “real-life” inhaled corticost...
RESULTS: The study included 63Â 900 patients with COPD aged 40Â years or older that were new users of 1 or more COPD medication of interest. Percent predicted FEV1 was available for 80.9% of patients; symptoms for 75.6% of patients. Classification into GOLD 2016 ABCD categories was ...